Vincristine Sulfate Liposome clinical trials
A product of Vincristine; its studies count on that page too.
How each study uses Vincristine Sulfate Liposome is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 10 Jul 1963 · ONCOVIN · NDA 014103 (FDA, Drugs@FDA; as Vincristine)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 4
Acrotech Biopharma Inc. (4) · Spectrum Pharmaceuticals, Inc (3) · Children's Oncology Group (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Brown University (1) · Wake Forest University Health Sciences (1) · Nanjing Luye Sike Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Rituximab (2) · Cyclophosphamide (1) · Dactinomycin (1) · Doxorubicin (1) · Etoposide (1) · Bendamustine (1)
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Vincristine
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses Vincristine Sulfate Liposome is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' TumorCompletedPhase 3Children's Oncology GroupNCT00379340Written as Vincristine Sulfate LiposomeHow we know
- Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction ChemotherapyCompletedPhase 1Therapeutic Advances in Childhood Leukemia ConsortiumNCT02879643Written as MarqiboHow we know
- Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell LymphomaCompletedPhase 1Brown UniversityNCT02257242Written as Vincristine sulfate liposome injectionHow we know
- A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALLTerminatedPhase 3Spectrum Pharmaceuticals, IncNCT01439347Written as Vincristine Sulfate Liposomes Injection (VSLI)How we know
- Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic LeukemiaCompletedPhase 2Spectrum Pharmaceuticals, IncNCT00495079Written as Marqibo® (vincristine sulfate liposomes injection)How we know
- PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant PatientsStatus unknownPhase 1Acrotech Biopharma Inc.NCT04243434Written as Vincristine Sulfate LiposomeHow we know
- To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory CancerCompletedPhase 1Acrotech Biopharma Inc.NCT01222780Written as MarqiboHow we know
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedPhase 1/2Acrotech Biopharma Inc.NCT01851551Written as Vincristine Sulfate Liposome Injection plus rituximabHow we know
- Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic DysfunctionCompletedPhase 1Acrotech Biopharma Inc.NCT00145041Written as Vincristine Sulfate Liposomes InjectionHow we know
- Safety and Efficacy of Marqibo in Metastatic Malignant Uveal MelanomaCompletedPhase 2Spectrum Pharmaceuticals, IncNCT00506142Written as Marqibo® (vincristine sulfate liposomes injection)How we know
- Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedPhase 2Wake Forest University Health SciencesNCT02337478Written as Vincristine Sulfate LiposomeHow we know
- Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic LeukemiaStatus unknownPhase 3Nanjing Luye Sike Pharmaceutical Co., Ltd.NCT02072785Written as Vincristine Sulfate LiposomeHow we know
Given beside what is tested · 7 — Vincristine Sulfate Liposome is usual care or a partner of the new treatment
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03136146Written as Vincristine Sulfate LiposomeHow we know
- Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk NeuroblastomaCompletedPhase 3Children's Oncology GroupNCT00567567Written as Vincristine Sulfate LiposomeHow we know
- Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic LeukemiaWithdrawnPhase 1/2Roswell Park Cancer InstituteNCT03851081Written as Vincristine Sulfate LiposomeHow we know
- Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 1/2Acrotech Biopharma Inc.NCT00144963Written as Vincristine Sulfate Liposomes InjectionHow we know
- Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic RhabdomyosarcomaCompletedPhase 2National Cancer Institute (NCI)NCT01055314Written as Vincristine Sulfate LiposomeHow we know
- Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's DiseaseCompletedPhase 3Children's Oncology GroupNCT00025259Written as Vincristine Sulfate LiposomeHow we know
- Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaWithdrawnPhase 1Northwestern UniversityNCT02861040Written as Vincristine Sulfate LiposomeHow we know